| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5656581 | Médecine des Maladies Métaboliques | 2017 | 7 Pages |
Abstract
The EMPA-REG OUTCOME trial and the LEADER trial will undoubtedly be landmark studies in the era of modern diabetology, as did the UKPDS and the DCCT. The decisionmaking criteria for the choice of antihyperglycemic agents became anachronistic in France. The presence of symptomatic cardiovascular diseases should become the top criteria for the choice of antihyperglycemic agents. Access to empagliflozin is necessary for the French type 2 diabetic (T2D) population. Liraglutide emerge as firstline choice for cardiovascular secondary prevention in T2D. An update of the French clinical practice guidelines is necessary.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
E. Disse,